| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Executive Summary
There is a plethora of new anti-angiogenic drugs in development. The potential
to block tumor growth and metastases by angiogenesis inhibition represents an
intriguing therapeutic strategy for the treatment of cancer and never before
have we seen as many anti-angiogenic drugs in clinical trials.
This report is written for you to identify your competition and understand
which targeting strategies are at work within anti-angiogenic drug development
in oncology. It allows you to pin-point which competitors drugs' clinical
out-come may have bearing on your own drug development and who are developing
sequels to blockbuster drugs. This report also helps you to locate white-spots
in the competitive landscape, giving you little or no competition. Conversly
it may reveal unexpected competition for you. First, BioSeeker has surveyed
anti-angiogenic drugs in oncology and identified 108 drug targets, belonging
to 123drugs. This report, Target Atlas: Competitive Insights to
Anti-Angiogenic Drug R&D in Oncology, is an open landscape of resources to
build, fuel, and drive your scientific competitive vehicle for the advancement
of new anti-angiogenic drugs in oncology.
In the report, BioSeeker reports on 88 unique drug target combinations, each
comprised of a different collection or mix of individually defined targets,
for 123 anti-angiogenic drugs designed for the treatment of 44 different
cancer indications. The highest degree of distinctiveness among
anti-angiogenic drugs is achieved by sorting each of them according to
targeted cancer indication, drug target mix, and drug compound type. At the
same time we are also identifying peer groups of drugs, that is, drugs we
consider suitable for head-to-head comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into
the presence and relevance of protein-protein interactions between identified
targets of anti-angiogenic drugs. No less than 162 protein-protein
interactions were recognized among and between 86 of the 108 included
anti-angiogenic drug targets.
Why You Should Own Your Own Copy of this Report:
- 230+ pages, with almost a hundred different tables and figures. Includes
more than 1,500 active links to related resources on the Internet
- 123 anti-angiogenic drugs, under development by 90 investigators, are
included, covering more than 361 developmental projects in cancer
- 108 Unique, in-depth, drug target profiles, highlighting twelve themes
about the drug target, i.e. protein-protein interaction with other
anti-angiogenic drug targets, linked cancer indications, drugs under
development, compound types, presence in the Cancer Genome Project etc.
- Unique 231 drug-protein target interactome analysis
- Unique drug target combination breakdown into 44 different cancer types
- Covers 88 unique drug target combinations of anti-angiogenic drugs
- 162 protein-protein interactions among and between anti-angiogenic drug
targets
- Pathway grouping of anti-angiogenic drug targets
- Pin-point which competitor drugs' clinical out-come may have bearing on
your own drug development
- Who are working on sequels to blockbuster drugs
- Locate white-spots in the competitive landscape, giving you little or no
competition
In all, this report is a serious reference for any professional interested in
the development of oncology drug targets and the selection/validation of
targeting strategies.
TABLE OF CONTENTS
1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 Table of Contents
- 4.1 List of Figures
- 4.2 List of Tables
5 How to Use this Report
6 Anti-Angiogenic Drug Compound Types and Sub-cellular Localizations of Targets
7 The Cancer Genome Project and Angiogenesis Drug Targets
- 7.1 Anti-Angiogenic Drug Targets Present in the Cancer Gene Census and in
the Catalogue Somatic Mutations in Cancer
8 Protein Expression Profiles of Anti-Angiogenic Drug Targets in Human
- 8.1 Expression in Normal Tissues and Cancer Tissues
- 8.2 Expression in Human Cancer Cell Lines and Primary Cells
9 Pathway Analysis of Anti-Angiogenic Drugs
10 Protein-Protein Interactions Among Identified Anti-Angiogenic Drug Targets
11 Available Biological Structure Data on Anti-Angiogenic Drug Targets
12 Drug Target Profiles of Anti-angiogenesis Drug Targets in Oncology
- 12.1.1 Carboxy-Lyase Activity
- 12.1.2 Catalytic Activity
- 12.1.3 Cell Adhesion Molecule Activity
- 12.1.4 Chaperone Activity
- 12.1.5 Cofactor Binding
- 12.1.6 Cysteine-Type Peptidase Activity
- 12.1.7 Cytokine Activity
- 12.1.8 DNA Topoisomerase Activity
- 12.1.9 DNA-Directed DNA Polymerase Activity
- 12.1.10 Extracellular Matrix Structural Constituent
- 12.1.11 G-Protein Coupled Receptor Activity
- 12.1.12 Growth Factor Activity
- 12.1.13 GTPase Activity
- 12.1.14 Hydrolase Activity
- 12.1.15 Kinase Activity
- 12.1.16 Lipid Kinase Activity
- 12.1.17 Metallopeptidase Activity
- 12.1.18 Molecular Function Unknown
- 12.1.19 Motor Activity
- 12.1.20 Peptidase Activity
- 12.1.21 Protease Inhibitor Activity
- 12.1.22 Protein Serine/Threonine Kinase Activity
- 12.1.23 Protein-Tyrosine Kinase Activity
- 12.1.24 Receptor Activity
- 12.1.25 Receptor Binding
- 12.1.26 Serine-Type Peptidase Activity
- 12.1.27 Structural Constituent of Cytoskeleton
- 12.1.28 Superoxide Dismutase Activity
- 12.1.29 Transcription Factor Activity
- 12.1.30 Transcription Regulator Activity
- 12.1.31 Translation Regulator Activity
- 12.1.32 Transmembrane Receptor Activity
- 12.1.33 Transmembrane Receptor Protein Tyrosine Kinase Activity
- 12.1.34 Transporter Activity
13 The Drug-Protein Interactome of Anti-Angiogenic Drugs
14 The Progression and Maturity of Anti-Angiogenic Drug Target Combinations
- 14.1 Target Profiles of Anti-Angiogenic Drugs on the Market
- 14.2 New Anti-Angiogenic Drug Target Combinations in Phase III Clinical
Development
- 14.3 New Anti-Angiogenic Drug Target Combinations in Phase II Clinical
Development
- 14.4 New Anti-Angiogenic Drug Target Combinations Phase I Clinical
Development
- 14.5 New Anti-Angiogenic Drug Target Combinations in Preclinical
Development
- 14.6 Development Profiles of All Identified Anti-Angiogenic Drug Target
Combinations
15 Anti-Angiogenic Drug Target Mix by Cancer Indication
- 15.1 Adrenal Cancer
- 15.2 Biliary Cancer
- 15.3 Bladder Cancer
- 15.4 Bone Cancer
- 15.5 Brain Cancer
- 15.6 Breast Cancer
- 15.7 Carcinoid Tumor
- 15.8 Cervical Cancer
- 15.9 Chemotherapy-Induced Infection
- 15.10 Colorectal Cancer
- 15.11 Endometrial Cancer
- 15.12 Fallopian Tube Cancer
- 15.13 Gastrointestinal Cancer
- 15.13.1 Gastrointestinal Stomach Cancer
- 15.13.2 Gastrointestinal Stromal Cancer
- 15.14 Head and Neck Cancer
- 15.15 Leukemia
- 15.15.1 Acute Lymphocytic Leukemia
- 15.15.2 Acute Myelogenous Leukemia
- 15.15.3 Chronic Lymphocytic Leukemia
- 15.15.4 Chronic Myelogenous Leukemia
- 15.16 Liver Cancer
- 15.17 Lung Cancer
- 15.17.1 Non-Small Cell Lung Cancer
- 15.17.2 Small Cell Lung Cancer
- 15.18 Lymphoma
- 15.18.1 B-Cell Lymphoma
- 15.18.2 Hodgkin's Lymphoma
- 15.18.3 Non-Hodgkin's Lymphoma
- 15.19 Melanoma
- 15.20 Mesothelioma
- 15.21 Myelodysplastic Syndrome
- 15.22 Myeloma
- 15.23 Nasopharyngeal Cancer
- 15.24 Oesophageal Cancer
- 15.25 Ovarian Cancer
- 15.26 Pancreatic Cancer
- 15.27 Peritoneal Cancer
- 15.28 Prostate Cancer
- 15.29 Renal Cancer
- 15.30 Sarcoma
- 15.31 Squamous Cell Cancer
- 15.32 Thyroid Cancer
16 Anti-Angiogenic Drugs and Their Targets by Companies
- 16.1 Australia
- 16.2 Austria
- 16.3 Belgium
- 16.4 Canada
- 16.5 China
- 16.6 Denmark
- 16.7 France
- 16.8 Germany
- 16.9 Israel
- 16.10 Japan
- 16.11 Netherlands
- 16.12 South Korea
- 16.13 Spain
- 16.14 Sweden
- 16.15 Switzerland
- 16.16 United Kingdom
- 16.17 USA
17 Disclaimer
18 Drug Index
19 Company Index
List of Figures
- Figure 1: Distribution of Compound Types Among Anti-Angiogenic Drugs
- Figure 2: Primary Sub-cellular Localization of Drug Targets
- Figure 3: Visualization of Protein-Protein Interactions Among
Anti-Angiogenic Drug Targets
- Figure 4: The Drug-Protein Interactome of Anti-Angiogenic Drugs
- Figure 5: Direct Head-to-Head Targeting Interactome of Anti-Angiogenic
Drugs
List of Tables
- Table 1: Compound Type Versus Primary and Alternate Localization of Drug
Target
- Table 2: Drug Targets of Anti-Angiogenic Drugs Present in the Catalogue of
Somatic Mutations in Cancer and in the Cancer Gene Census
- Table 3: Available Protein Expression Profiles of Anti-Angiogenic Drug
Targets
- Table 4: Pathway Summary
- Table 5: Drug Targets Without any Identified Assigned Pathways
- Table 6: Pathway Profile According to BioCarta of the Anti-Angiogenic Drug
Targets
- Table 7: Pathway Profile According to KEGG of the Anti-Angiogenic Drug
Targets
- Table 8: Anti-Angiogenic Drugs Targeting Major Singaling Pathways
- Table 9: Protein-Protein Interactions Among Anti-Angiogenic Drug Targets
- Table 10: Number of Available Biological Structures on Anti-Angiogenic
Drug Targets
- Table 11: Overview of Drug Target Profile Themes
- Table 12: Drug-Protein Clusters in the Anti-Angiogenic Interactome
- Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes,
Drugs, Developmental Projects, and the Presence of New Drug Target Mixes by
Developmental Stage
- Table 14: Target Profiles of Anti-Angiogenic Drugs on the Market
- Table 15: New Anti-Angiogenic Drug Target Combinations in Phase III
Clinical Development
- Table 16: New Anti-Angiogenic Drug Target Combinations in Phase II
Clinical Development
- Table 17 New Anti-Angiogenic Drug Target Combinations Phase I Clinical
Development
- Table 18: New Anti-Angiogenic Drug Target Combinations in Preclinical
Development
- Table 19: The Progression, Maturity and Comptitive Comparison of
Anti-Angiogenic Drug Target Mixes in Development
- Table 20: Number of Unique Anti-angiogenic Drug Target Mixes Reported by
Cancer Indication
- Table 21: The Competitive Situation on Bevacizumab (Avastin)
- Table 22: Anti-angiogenic Drug Target Mix for the Treatment of Adrenal
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 23: Anti-angiogenic Drug Target Mix for the Treatment of Biliary
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 24: Anti-angiogenic Drug Target Mix for the Treatment of Bladder
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 25: Anti-angiogenic Drug Target Mix for the Treatment of Bone Cancer
According to the Compound Type and Developmental Stage of Drug
- Table 26: Anti-angiogenic Drug Target Mix for the Treatment of Brain
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 27: Anti-angiogenic Drug Target Mix for the Treatment of Breast
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 28: Anti-angiogenic Drug Target Mix for the Treatment of Carcinoid
Tumor According to the Compound Type and Developmental Stage of Drug
- Table 29: Anti-angiogenic Drug Target Mix for the Treatment of Cervical
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 30: Anti-angiogenic Drug Target Mix for the Treatment of
Chemotherapy-induced Infection According to the Compound Type and
Developmental Stage of Drug
- Table 31: Anti-angiogenic Drug Target Mix for the Treatment of Colorectal
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 32: Anti-angiogenic Drug Target Mix for the Treatment of Endometrial
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 33: Anti-angiogenic Drug Target Mix for the Treatment of Fallopian
Tube Cancer According to the Compound Type and Developmental Stage of Drug
- Table 34: Anti-angiogenic Drug Target Mix for the Treatment of
Gastrointestinal Cancer (General) According to the Compound Type and
Developmental Stage of Drug
- Table 35: Anti-angiogenic Drug Target Mix for the Treatment of
Gastrointestinal Stomach Cancer According to the Compound Type and
Developmental Stage of Drug
- Table 36: Anti-angiogenic Drug Target Mix for the Treatment of
Gastrointestinal Stromal Cancer According to the Compound Type and
Developmental Stage of Drug
- Table 37: Anti-angiogenic Drug Target Mix for the Treatment of Head and
Neck Cancer According to the Compound Type and Developmental Stage of Drug
- Table 38: Anti-angiogenic Drug Target Mix for the Treatment of Leukemia
(General) According to the Compound Type and Developmental Stage of Drug
- Table 39: Anti-angiogenic Drug Target Mix for the Treatment of Acute
Lymphocytic Leukemia According to the Compound Type and Developmental Stage of
Drug
- Table 40: Anti-angiogenic Drug Target Mix for the Treatment of Acute
Myelogenous Leukemia According to the Compound Type and Developmental Stage of
Drug
- Table 41: Anti-angiogenic Drug Target Mix for the Treatment of Chronic
Lymphocytic Leukemia Cancer According to the Compound Type and Developmental
Stage of Drug
- Table 42: Anti-angiogenic Drug Target Mix for the Treatment of Chronic
Myelogenous Leukemia Cancer According to the Compound Type and Developmental
Stage of Drug
- Table 43: Anti-angiogenic Drug Target Mix for the Treatment of Liver
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 44: Anti-angiogenic Drug Target Mix for the Treatment of Lung Cancer
(General) According to the Compound Type and Developmental Stage of Drug
- Table 45: Anti-angiogenic Drug Target Mix for the Treatment of Non-Small
Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
- Table 46: Anti-angiogenic Drug Target Mix for the Treatment of Small Cell
Lung Cancer According to the Compound Type and Developmental Stage of Drug
- Table 47: Anti-angiogenic Drug Target Mix for the Treatment of Lymphoma
(General) According to the Compound Type and Developmental Stage of Drug
- Table 48: Anti-angiogenic Drug Target Mix for the Treatment of B-Cell
Lymphoma According to the Compound Type and Developmental Stage of Drug
- Table 49: Anti-angiogenic Drug Target Mix for the Treatment of Hodgkin's
Lymphoma According to the Compound Type and Developmental Stage of Drug
- Table 50: Anti-angiogenic Drug Target Mix for the Treatment of
Non-Hodgkin's Lymphoma According to the Compound Type and Developmental Stage
of Drug
- Table 51: Anti-angiogenic Drug Target Mix for the Treatment of Melanoma
According to the Compound Type and Developmental Stage of Drug
- Table 52: Anti-angiogenic Drug Target Mix for the Treatment of
Mesothelioma According to the Compound Type and Developmental Stage of Drug
- Table 53: Anti-angiogenic Drug Target Mix for the Treatment of
Myelodysplastic Syndrome According to the Compound Type and Developmental
Stage of Drug
- Table 54: Anti-angiogenic Drug Target Mix for the Treatment of Myeloma
According to the Compound Type and Developmental Stage of Drug
- Table 55: Anti-angiogenic Drug Target Mix for the Treatment of
Nasopharyngeal Cancer According to the Compound Type and Developmental Stage
of Drug
- Table 56: Anti-angiogenic Drug Target Mix for the Treatment of Oesophageal
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 57: Anti-angiogenic Drug Target Mix for the Treatment of Ovarian
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 58: Anti-angiogenic Drug Target Mix for the Treatment of Pancreatic
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 59: Anti-angiogenic Drug Target Mix for the Treatment of Peritoneal
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 60: Anti-angiogenic Drug Target Mix for the Treatment of Prostate
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 61: Anti-angiogenic Drug Target Mix for the Treatment of Renal
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 62: Anti-angiogenic Drug Target Mix for the Treatment of Sarcoma
(General) According to the Compound Type and Developmental Stage of Drug
- Table 63: Anti-angiogenic Drug Target Mix for the Treatment of Leiomyo
Sarcoma According to the Compound Type and Developmental Stage of Drug
- Table 64: Anti-angiogenic Drug Target Mix for the Treatment of Squamous
Cell Cancer According to the Compound Type and Developmental Stage of Drug
- Table 65: Anti-angiogenic Drug Target Mix for the Treatment of Thyroid
Cancer According to the Compound Type and Developmental Stage of Drug
- Table 66: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in Australia
- Table 67: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in Austria
- Table 68: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in Belgium
- Table 69: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in Canada
- Table 70: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in China
- Table 71: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in Denmark
- Table 72: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in France
- Table 73; Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in Germany
- Table 74: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in Israel
- Table 75: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in Japan
- Table 76: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in the Netherlands
- Table 77: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in South Korea
- Table 78: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in South Korea
- Table 79: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in Sweden
- Table 80: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in Switzerland
- Table 81: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in United Kingdom
- Table 82: Anti-angiogenic drugs with Target Mix and Developmental Projects
by Companies in USA
|
